Portal de investigación
Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Iraola-Truchuelo, Josu
- Mussetti, Alberto
- Fernandez-Caldas, Paula
- Navarro Garces, Victor
- Martin Lopez, Ana Africa
- Perez Martinez, Ariadna
- Carolina Caballero Gonzalez, Ana Carolina
- Martinez-Cibrian, Nuria
- Luzardo Henriquez, Hugo Daniel
- Sanchez, Jose M.
- Sancho, Juan-Manuel
- Barba, Pere
- Kwon, Mi
- Lopez Corral, Lucia
- Luis Reguera, Juan
- Martin Garcia-Sancho, Alejandro
- Bastos-Oreiro, Mariana
- Abrisqueta, Pau
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Citas Recibidas en Web of Science: 17
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Iacoboni,G,Iraola,J,Mussetti,A,Fernandez,P,Navarro,V,Martin,AA,Delgado,J et al. Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2022.